The anti-cancer immune response in breast cancer: current and emerging biomarkers and treatments
Trends in Cancer · 2024-06 · 10 (6) · 490-506
DOI: 10.1016/j.trecan.2024.02.008 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Trends in Cancer, 2024-06. Verfasst von Victoria C Rayson und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Biomarkers, Tumor, Immune Checkpoint Inhibitors, Tumor Microenvironment. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 103 Literaturangaben. Gefördert von: Breast Cancer Research Foundation, National Health and Medical Research Council, Mount Sylvia Diatomite.
Abstract (Originalsprache)
Triple-negative breast cancers (TNBCs) exhibit heightened T cell infiltration, contributing to an enhanced response to immune checkpoint blockade (ICB) compared with other subtypes. An immune-rich immune microenvironment correlates with improved prognosis in early and advanced TNBC. Combination chemotherapy and ICB is now the standard of care in early- and late-stage TNBC. Although programmed death ligand-1 (PD-L1) positivity predicts ICB response in advanced stages, its role in early-stage disease remains uncertain. Despite neoadjuvant ICB becoming common in early-stage TNBC, the necessity of adjuvant ICB after surgery remains unclear. Understanding the molecular basis of the immune response in breast cancer is vital for precise biomarkers for ICB and effective combination therapy strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
- The Sir Peter MacCallum Department of Medical Oncology, University of Melbourne, Melbourne, Victoria, Australia; Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
- Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; The Sir Peter MacCallum Department of Medical Oncology, University of Melbourne, Melbourne, Victoria, Australia; Division of…
- Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
- Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Department of Pathology, GZA-ZNA Hospitals, Antwerp, Belgium.
Förderung
- Breast Cancer Research Foundation
- National Health and Medical Research Council
- Mount Sylvia Diatomite
- AstraZeneca
- National Breast Cancer Foundation
Zitieren
APA
Rayson, V. C., Harris, M. A., Savas, P., Hun, M. L., Virassamy, B., Salgado, R., & Loi, S. (2024). The anti-cancer immune response in breast cancer: current and emerging biomarkers and treatments. Trends in Cancer, 10(6), 490-506. https://doi.org/10.1016/j.trecan.2024.02.008
Vancouver
Rayson VC, Harris MA, Savas P, Hun ML, Virassamy B, Salgado R, et al. The anti-cancer immune response in breast cancer: current and emerging biomarkers and treatments. Trends in Cancer. 2024;10(6):490-506. doi:10.1016/j.trecan.2024.02.008
BibTeX
@article{Rayson2024,
author = {Rayson, Victoria C and Harris, Michael A and Savas, Peter and Hun, Michael L and Virassamy, Balaji and Salgado, Roberto and Loi, Sherene},
title = {The anti-cancer immune response in breast cancer: current and emerging biomarkers and treatments},
journal = {Trends in Cancer},
year = {2024},
volume = {10},
number = {6},
pages = {490--506},
doi = {10.1016/j.trecan.2024.02.008}
}
EUVIMED